nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—CYP2A6—Progesterone—uterine cancer	0.141	0.197	CbGbCtD
Rosiglitazone—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.105	0.147	CbGbCtD
Rosiglitazone—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0733	0.102	CbGbCtD
Rosiglitazone—CYP2C8—Progesterone—uterine cancer	0.0696	0.0971	CbGbCtD
Rosiglitazone—CYP2C19—Progesterone—uterine cancer	0.0584	0.0814	CbGbCtD
Rosiglitazone—PTGS1—Etoposide—uterine cancer	0.054	0.0753	CbGbCtD
Rosiglitazone—CYP1A2—Progesterone—uterine cancer	0.0539	0.0751	CbGbCtD
Rosiglitazone—CYP2C9—Progesterone—uterine cancer	0.0486	0.0677	CbGbCtD
Rosiglitazone—CYP2D6—Progesterone—uterine cancer	0.0444	0.0619	CbGbCtD
Rosiglitazone—CYP2C8—Etoposide—uterine cancer	0.0312	0.0434	CbGbCtD
Rosiglitazone—CYP1A2—Etoposide—uterine cancer	0.0241	0.0336	CbGbCtD
Rosiglitazone—CYP2D6—Doxorubicin—uterine cancer	0.0136	0.0189	CbGbCtD
Rosiglitazone—Macular oedema—Medroxyprogesterone Acetate—uterine cancer	0.00812	0.0544	CcSEcCtD
Rosiglitazone—ACSL4—myometrium—uterine cancer	0.00487	0.0597	CbGeAlD
Rosiglitazone—PPARG—artery—uterine cancer	0.00453	0.0556	CbGeAlD
Rosiglitazone—PPARG—Teniposide—Etoposide—uterine cancer	0.00388	1	CbGdCrCtD
Rosiglitazone—ACSL4—uterine cervix—uterine cancer	0.00379	0.0465	CbGeAlD
Rosiglitazone—PTGS1—oviduct—uterine cancer	0.00366	0.0449	CbGeAlD
Rosiglitazone—ACSL4—decidua—uterine cancer	0.00361	0.0443	CbGeAlD
Rosiglitazone—ACSL4—renal system—uterine cancer	0.00354	0.0435	CbGeAlD
Rosiglitazone—ACSL4—endometrium—uterine cancer	0.00343	0.042	CbGeAlD
Rosiglitazone—ACSL4—mammalian vulva—uterine cancer	0.00331	0.0407	CbGeAlD
Rosiglitazone—ACSL4—uterus—uterine cancer	0.00316	0.0387	CbGeAlD
Rosiglitazone—ACSL4—female reproductive system—uterine cancer	0.00284	0.0348	CbGeAlD
Rosiglitazone—ACSL4—female gonad—uterine cancer	0.00258	0.0317	CbGeAlD
Rosiglitazone—ACSL4—vagina—uterine cancer	0.00257	0.0315	CbGeAlD
Rosiglitazone—PTGS1—artery—uterine cancer	0.00242	0.0297	CbGeAlD
Rosiglitazone—Hepatic enzyme increased—Progesterone—uterine cancer	0.00231	0.0155	CcSEcCtD
Rosiglitazone—Fluid retention—Progesterone—uterine cancer	0.00208	0.0139	CcSEcCtD
Rosiglitazone—Fluid retention—Medroxyprogesterone Acetate—uterine cancer	0.00188	0.0126	CcSEcCtD
Rosiglitazone—SLCO1B1—renal system—uterine cancer	0.00185	0.0227	CbGeAlD
Rosiglitazone—Hepatic function abnormal—Progesterone—uterine cancer	0.00182	0.0122	CcSEcCtD
Rosiglitazone—Hepatic failure—Progesterone—uterine cancer	0.00177	0.0118	CcSEcCtD
Rosiglitazone—PPARG—epithelium—uterine cancer	0.00172	0.0211	CbGeAlD
Rosiglitazone—Increased appetite—Progesterone—uterine cancer	0.00169	0.0113	CcSEcCtD
Rosiglitazone—ACSL4—lymph node—uterine cancer	0.00166	0.0204	CbGeAlD
Rosiglitazone—PPARG—smooth muscle tissue—uterine cancer	0.00166	0.0203	CbGeAlD
Rosiglitazone—Diabetes mellitus—Medroxyprogesterone Acetate—uterine cancer	0.00165	0.0111	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00165	0.011	CcSEcCtD
Rosiglitazone—PPARG—decidua—uterine cancer	0.00162	0.0199	CbGeAlD
Rosiglitazone—Hepatic failure—Medroxyprogesterone Acetate—uterine cancer	0.0016	0.0107	CcSEcCtD
Rosiglitazone—PPARG—renal system—uterine cancer	0.00159	0.0196	CbGeAlD
Rosiglitazone—Cardiac failure congestive—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.0106	CcSEcCtD
Rosiglitazone—Increased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00153	0.0103	CcSEcCtD
Rosiglitazone—PPARG—mammalian vulva—uterine cancer	0.00149	0.0183	CbGeAlD
Rosiglitazone—SLCO1B1—female reproductive system—uterine cancer	0.00148	0.0182	CbGeAlD
Rosiglitazone—Infection—Carboplatin—uterine cancer	0.00148	0.00989	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.00988	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.00984	CcSEcCtD
Rosiglitazone—PPARG—uterus—uterine cancer	0.00142	0.0174	CbGeAlD
Rosiglitazone—Nasopharyngitis—Progesterone—uterine cancer	0.00142	0.00951	CcSEcCtD
Rosiglitazone—CYP2A6—vagina—uterine cancer	0.00136	0.0166	CbGeAlD
Rosiglitazone—Nasopharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00862	CcSEcCtD
Rosiglitazone—PPARG—female reproductive system—uterine cancer	0.00128	0.0157	CbGeAlD
Rosiglitazone—Upper respiratory tract infection—Progesterone—uterine cancer	0.00128	0.00855	CcSEcCtD
Rosiglitazone—Weight increased—Progesterone—uterine cancer	0.00125	0.00837	CcSEcCtD
Rosiglitazone—Hepatic failure—Dactinomycin—uterine cancer	0.00125	0.00837	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Progesterone—uterine cancer	0.00124	0.00829	CcSEcCtD
Rosiglitazone—PPARG—female gonad—uterine cancer	0.00116	0.0143	CbGeAlD
Rosiglitazone—Hepatobiliary disease—Progesterone—uterine cancer	0.00116	0.00775	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00774	CcSEcCtD
Rosiglitazone—PPARG—vagina—uterine cancer	0.00115	0.0142	CbGeAlD
Rosiglitazone—Sinusitis—Progesterone—uterine cancer	0.00115	0.00769	CcSEcCtD
Rosiglitazone—Weight increased—Medroxyprogesterone Acetate—uterine cancer	0.00113	0.00758	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00112	0.00752	CcSEcCtD
Rosiglitazone—Hepatitis—Progesterone—uterine cancer	0.0011	0.00736	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	0.00109	0.00732	CcSEcCtD
Rosiglitazone—Myocardial infarction—Medroxyprogesterone Acetate—uterine cancer	0.00109	0.00728	CcSEcCtD
Rosiglitazone—Oedema peripheral—Progesterone—uterine cancer	0.00108	0.00725	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Progesterone—uterine cancer	0.00108	0.00723	CcSEcCtD
Rosiglitazone—CYP2C8—renal system—uterine cancer	0.00105	0.0129	CbGeAlD
Rosiglitazone—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00703	CcSEcCtD
Rosiglitazone—Sinusitis—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00697	CcSEcCtD
Rosiglitazone—Erythema multiforme—Progesterone—uterine cancer	0.00104	0.00696	CcSEcCtD
Rosiglitazone—Eye disorder—Progesterone—uterine cancer	0.00103	0.00688	CcSEcCtD
Rosiglitazone—Cardiac disorder—Progesterone—uterine cancer	0.00102	0.00683	CcSEcCtD
Rosiglitazone—CYP2C8—endometrium—uterine cancer	0.00102	0.0125	CbGeAlD
Rosiglitazone—Hepatitis—Medroxyprogesterone Acetate—uterine cancer	0.000996	0.00667	CcSEcCtD
Rosiglitazone—Immune system disorder—Progesterone—uterine cancer	0.000993	0.00665	CcSEcCtD
Rosiglitazone—CYP1A2—renal system—uterine cancer	0.000984	0.0121	CbGeAlD
Rosiglitazone—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.000981	0.00657	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.000978	0.00655	CcSEcCtD
Rosiglitazone—Malnutrition—Progesterone—uterine cancer	0.000957	0.00641	CcSEcCtD
Rosiglitazone—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.000941	0.00631	CcSEcCtD
Rosiglitazone—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.000931	0.00623	CcSEcCtD
Rosiglitazone—Back pain—Progesterone—uterine cancer	0.000925	0.0062	CcSEcCtD
Rosiglitazone—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.000924	0.00619	CcSEcCtD
Rosiglitazone—PTGS1—epithelium—uterine cancer	0.000919	0.0113	CbGeAlD
Rosiglitazone—PTGS1—uterine cervix—uterine cancer	0.000911	0.0112	CbGeAlD
Rosiglitazone—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000899	0.00602	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Etoposide—uterine cancer	0.000896	0.006	CcSEcCtD
Rosiglitazone—PTGS1—smooth muscle tissue—uterine cancer	0.000886	0.0109	CbGeAlD
Rosiglitazone—Anaemia—Progesterone—uterine cancer	0.000884	0.00592	CcSEcCtD
Rosiglitazone—Angioedema—Progesterone—uterine cancer	0.000874	0.00585	CcSEcCtD
Rosiglitazone—CYP2C19—vagina—uterine cancer	0.000872	0.0107	CbGeAlD
Rosiglitazone—Hyperlipidaemia—Epirubicin—uterine cancer	0.000871	0.00583	CcSEcCtD
Rosiglitazone—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000867	0.00581	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.000858	0.00575	CcSEcCtD
Rosiglitazone—PTGS1—renal system—uterine cancer	0.000852	0.0105	CbGeAlD
Rosiglitazone—CYP2C8—female reproductive system—uterine cancer	0.000842	0.0103	CbGeAlD
Rosiglitazone—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000838	0.00562	CcSEcCtD
Rosiglitazone—Cardiac failure—Etoposide—uterine cancer	0.000833	0.00558	CcSEcCtD
Rosiglitazone—Hypertension—Progesterone—uterine cancer	0.000826	0.00553	CcSEcCtD
Rosiglitazone—PTGS1—endometrium—uterine cancer	0.000824	0.0101	CbGeAlD
Rosiglitazone—Pleural effusion—Epirubicin—uterine cancer	0.000819	0.00549	CcSEcCtD
Rosiglitazone—Arthralgia—Progesterone—uterine cancer	0.000814	0.00545	CcSEcCtD
Rosiglitazone—Myalgia—Progesterone—uterine cancer	0.000814	0.00545	CcSEcCtD
Rosiglitazone—Hyperlipidaemia—Doxorubicin—uterine cancer	0.000805	0.0054	CcSEcCtD
Rosiglitazone—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.000801	0.00537	CcSEcCtD
Rosiglitazone—PTGS1—mammalian vulva—uterine cancer	0.000797	0.00978	CbGeAlD
Rosiglitazone—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000792	0.00531	CcSEcCtD
Rosiglitazone—Oedema—Progesterone—uterine cancer	0.000781	0.00523	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Progesterone—uterine cancer	0.000781	0.00523	CcSEcCtD
Rosiglitazone—Hepatitis—Dactinomycin—uterine cancer	0.000777	0.0052	CcSEcCtD
Rosiglitazone—Infection—Progesterone—uterine cancer	0.000776	0.00519	CcSEcCtD
Rosiglitazone—Nervous system disorder—Progesterone—uterine cancer	0.000766	0.00513	CcSEcCtD
Rosiglitazone—CYP2C8—vagina—uterine cancer	0.000761	0.00934	CbGeAlD
Rosiglitazone—PTGS1—uterus—uterine cancer	0.000759	0.00931	CbGeAlD
Rosiglitazone—Pleural effusion—Doxorubicin—uterine cancer	0.000758	0.00508	CcSEcCtD
Rosiglitazone—CYP2C9—female reproductive system—uterine cancer	0.000748	0.00917	CbGeAlD
Rosiglitazone—PPARG—lymph node—uterine cancer	0.000747	0.00916	CbGeAlD
Rosiglitazone—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000738	0.00494	CcSEcCtD
Rosiglitazone—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.000738	0.00494	CcSEcCtD
Rosiglitazone—Erythema multiforme—Dactinomycin—uterine cancer	0.000734	0.00492	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000711	0.00476	CcSEcCtD
Rosiglitazone—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000707	0.00474	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000707	0.00474	CcSEcCtD
Rosiglitazone—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000703	0.00471	CcSEcCtD
Rosiglitazone—ALB—lymph node—uterine cancer	0.000701	0.00859	CbGeAlD
Rosiglitazone—CYP2D6—renal system—uterine cancer	0.000701	0.00859	CbGeAlD
Rosiglitazone—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000694	0.00465	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000693	0.00464	CcSEcCtD
Rosiglitazone—Hyperbilirubinaemia—Epirubicin—uterine cancer	0.00069	0.00462	CcSEcCtD
Rosiglitazone—PTGS1—female reproductive system—uterine cancer	0.000683	0.00837	CbGeAlD
Rosiglitazone—Gastrointestinal disorder—Progesterone—uterine cancer	0.000674	0.00451	CcSEcCtD
Rosiglitazone—Fatigue—Progesterone—uterine cancer	0.000673	0.00451	CcSEcCtD
Rosiglitazone—Constipation—Progesterone—uterine cancer	0.000668	0.00447	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000645	0.00432	CcSEcCtD
Rosiglitazone—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.000638	0.00428	CcSEcCtD
Rosiglitazone—Anaemia—Dactinomycin—uterine cancer	0.000625	0.00419	CcSEcCtD
Rosiglitazone—PTGS1—female gonad—uterine cancer	0.000621	0.00762	CbGeAlD
Rosiglitazone—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000621	0.00416	CcSEcCtD
Rosiglitazone—Urticaria—Progesterone—uterine cancer	0.00062	0.00415	CcSEcCtD
Rosiglitazone—PTGS1—vagina—uterine cancer	0.000617	0.00757	CbGeAlD
Rosiglitazone—Acute coronary syndrome—Etoposide—uterine cancer	0.000617	0.00413	CcSEcCtD
Rosiglitazone—Myocardial infarction—Etoposide—uterine cancer	0.000614	0.00411	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000611	0.00409	CcSEcCtD
Rosiglitazone—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00061	0.00409	CcSEcCtD
Rosiglitazone—Leukopenia—Dactinomycin—uterine cancer	0.000605	0.00405	CcSEcCtD
Rosiglitazone—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000605	0.00405	CcSEcCtD
Rosiglitazone—Fluid retention—Epirubicin—uterine cancer	0.000596	0.00399	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Etoposide—uterine cancer	0.000592	0.00397	CcSEcCtD
Rosiglitazone—Myalgia—Dactinomycin—uterine cancer	0.000576	0.00386	CcSEcCtD
Rosiglitazone—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000562	0.00376	CcSEcCtD
Rosiglitazone—CYP2D6—female reproductive system—uterine cancer	0.000561	0.00688	CbGeAlD
Rosiglitazone—Asthenia—Progesterone—uterine cancer	0.00056	0.00375	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Epirubicin—uterine cancer	0.000559	0.00374	CcSEcCtD
Rosiglitazone—Pruritus—Progesterone—uterine cancer	0.000552	0.0037	CcSEcCtD
Rosiglitazone—Oedema—Dactinomycin—uterine cancer	0.000552	0.0037	CcSEcCtD
Rosiglitazone—Fluid retention—Doxorubicin—uterine cancer	0.000551	0.00369	CcSEcCtD
Rosiglitazone—Infection—Dactinomycin—uterine cancer	0.000548	0.00367	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Dactinomycin—uterine cancer	0.00054	0.00362	CcSEcCtD
Rosiglitazone—Diarrhoea—Progesterone—uterine cancer	0.000534	0.00358	CcSEcCtD
Rosiglitazone—Erythema multiforme—Etoposide—uterine cancer	0.000531	0.00356	CcSEcCtD
Rosiglitazone—Eye disorder—Etoposide—uterine cancer	0.000525	0.00352	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Epirubicin—uterine cancer	0.000524	0.00351	CcSEcCtD
Rosiglitazone—Cardiac disorder—Etoposide—uterine cancer	0.000522	0.00349	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Epirubicin—uterine cancer	0.000521	0.00349	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Doxorubicin—uterine cancer	0.000517	0.00346	CcSEcCtD
Rosiglitazone—Dizziness—Progesterone—uterine cancer	0.000516	0.00346	CcSEcCtD
Rosiglitazone—CYP2D6—female gonad—uterine cancer	0.000511	0.00626	CbGeAlD
Rosiglitazone—Immune system disorder—Etoposide—uterine cancer	0.000508	0.0034	CcSEcCtD
Rosiglitazone—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000508	0.0034	CcSEcCtD
Rosiglitazone—Hepatic failure—Epirubicin—uterine cancer	0.000507	0.00339	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000503	0.00337	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Epirubicin—uterine cancer	0.000502	0.00336	CcSEcCtD
Rosiglitazone—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000501	0.00335	CcSEcCtD
Rosiglitazone—Rash—Progesterone—uterine cancer	0.000492	0.0033	CcSEcCtD
Rosiglitazone—Dermatitis—Progesterone—uterine cancer	0.000492	0.00329	CcSEcCtD
Rosiglitazone—Headache—Progesterone—uterine cancer	0.000489	0.00328	CcSEcCtD
Rosiglitazone—Increased appetite—Epirubicin—uterine cancer	0.000485	0.00325	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Doxorubicin—uterine cancer	0.000485	0.00325	CcSEcCtD
Rosiglitazone—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000484	0.00324	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000482	0.00323	CcSEcCtD
Rosiglitazone—Fatigue—Dactinomycin—uterine cancer	0.000476	0.00319	CcSEcCtD
Rosiglitazone—Back pain—Etoposide—uterine cancer	0.000473	0.00317	CcSEcCtD
Rosiglitazone—Hepatic failure—Doxorubicin—uterine cancer	0.000469	0.00314	CcSEcCtD
Rosiglitazone—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000468	0.00313	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Epirubicin—uterine cancer	0.000467	0.00313	CcSEcCtD
Rosiglitazone—Cardiac failure—Epirubicin—uterine cancer	0.000467	0.00313	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Epirubicin—uterine cancer	0.000465	0.00311	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000465	0.00311	CcSEcCtD
Rosiglitazone—Nausea—Progesterone—uterine cancer	0.000464	0.00311	CcSEcCtD
Rosiglitazone—Anaemia—Etoposide—uterine cancer	0.000452	0.00303	CcSEcCtD
Rosiglitazone—Increased appetite—Doxorubicin—uterine cancer	0.000449	0.003	CcSEcCtD
Rosiglitazone—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000446	0.00299	CcSEcCtD
Rosiglitazone—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000446	0.00298	CcSEcCtD
Rosiglitazone—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000443	0.00297	CcSEcCtD
Rosiglitazone—Leukopenia—Etoposide—uterine cancer	0.000438	0.00293	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Doxorubicin—uterine cancer	0.000432	0.00289	CcSEcCtD
Rosiglitazone—Cardiac failure—Doxorubicin—uterine cancer	0.000432	0.00289	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Doxorubicin—uterine cancer	0.00043	0.00288	CcSEcCtD
Rosiglitazone—Hypertension—Etoposide—uterine cancer	0.000422	0.00283	CcSEcCtD
Rosiglitazone—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00042	0.00281	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Epirubicin—uterine cancer	0.000407	0.00273	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Etoposide—uterine cancer	0.000399	0.00267	CcSEcCtD
Rosiglitazone—PTGS1—lymph node—uterine cancer	0.000399	0.0049	CbGeAlD
Rosiglitazone—Infection—Etoposide—uterine cancer	0.000397	0.00266	CcSEcCtD
Rosiglitazone—Asthenia—Dactinomycin—uterine cancer	0.000396	0.00265	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Etoposide—uterine cancer	0.000391	0.00262	CcSEcCtD
Rosiglitazone—Diarrhoea—Dactinomycin—uterine cancer	0.000378	0.00253	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Doxorubicin—uterine cancer	0.000377	0.00252	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000366	0.00245	CcSEcCtD
Rosiglitazone—Weight increased—Epirubicin—uterine cancer	0.000358	0.0024	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Epirubicin—uterine cancer	0.000355	0.00238	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000348	0.00233	CcSEcCtD
Rosiglitazone—Rash—Dactinomycin—uterine cancer	0.000348	0.00233	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Etoposide—uterine cancer	0.000345	0.00231	CcSEcCtD
Rosiglitazone—Fatigue—Etoposide—uterine cancer	0.000344	0.00231	CcSEcCtD
Rosiglitazone—Constipation—Etoposide—uterine cancer	0.000342	0.00229	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000339	0.00227	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Epirubicin—uterine cancer	0.000332	0.00222	CcSEcCtD
Rosiglitazone—Weight increased—Doxorubicin—uterine cancer	0.000331	0.00222	CcSEcCtD
Rosiglitazone—Sinusitis—Epirubicin—uterine cancer	0.000329	0.00221	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Doxorubicin—uterine cancer	0.000329	0.0022	CcSEcCtD
Rosiglitazone—Nausea—Dactinomycin—uterine cancer	0.000328	0.0022	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000322	0.00216	CcSEcCtD
Rosiglitazone—Urticaria—Etoposide—uterine cancer	0.000317	0.00213	CcSEcCtD
Rosiglitazone—Hepatitis—Epirubicin—uterine cancer	0.000315	0.00211	CcSEcCtD
Rosiglitazone—Oedema peripheral—Epirubicin—uterine cancer	0.00031	0.00208	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Epirubicin—uterine cancer	0.00031	0.00207	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000307	0.00206	CcSEcCtD
Rosiglitazone—Sinusitis—Doxorubicin—uterine cancer	0.000305	0.00204	CcSEcCtD
Rosiglitazone—Erythema multiforme—Epirubicin—uterine cancer	0.000298	0.002	CcSEcCtD
Rosiglitazone—Eye disorder—Epirubicin—uterine cancer	0.000294	0.00197	CcSEcCtD
Rosiglitazone—Cardiac disorder—Epirubicin—uterine cancer	0.000292	0.00196	CcSEcCtD
Rosiglitazone—Hepatitis—Doxorubicin—uterine cancer	0.000292	0.00195	CcSEcCtD
Rosiglitazone—Oedema peripheral—Doxorubicin—uterine cancer	0.000287	0.00192	CcSEcCtD
Rosiglitazone—Asthenia—Etoposide—uterine cancer	0.000287	0.00192	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Doxorubicin—uterine cancer	0.000287	0.00192	CcSEcCtD
Rosiglitazone—Immune system disorder—Epirubicin—uterine cancer	0.000285	0.00191	CcSEcCtD
Rosiglitazone—Pruritus—Etoposide—uterine cancer	0.000283	0.00189	CcSEcCtD
Rosiglitazone—Erythema multiforme—Doxorubicin—uterine cancer	0.000276	0.00185	CcSEcCtD
Rosiglitazone—Malnutrition—Epirubicin—uterine cancer	0.000274	0.00184	CcSEcCtD
Rosiglitazone—Diarrhoea—Etoposide—uterine cancer	0.000273	0.00183	CcSEcCtD
Rosiglitazone—Eye disorder—Doxorubicin—uterine cancer	0.000272	0.00182	CcSEcCtD
Rosiglitazone—Cardiac disorder—Doxorubicin—uterine cancer	0.000271	0.00181	CcSEcCtD
Rosiglitazone—Back pain—Epirubicin—uterine cancer	0.000265	0.00178	CcSEcCtD
Rosiglitazone—Dizziness—Etoposide—uterine cancer	0.000264	0.00177	CcSEcCtD
Rosiglitazone—Immune system disorder—Doxorubicin—uterine cancer	0.000263	0.00176	CcSEcCtD
Rosiglitazone—Malnutrition—Doxorubicin—uterine cancer	0.000254	0.0017	CcSEcCtD
Rosiglitazone—Anaemia—Epirubicin—uterine cancer	0.000254	0.0017	CcSEcCtD
Rosiglitazone—Rash—Etoposide—uterine cancer	0.000252	0.00169	CcSEcCtD
Rosiglitazone—Dermatitis—Etoposide—uterine cancer	0.000252	0.00169	CcSEcCtD
Rosiglitazone—Headache—Etoposide—uterine cancer	0.00025	0.00168	CcSEcCtD
Rosiglitazone—Leukopenia—Epirubicin—uterine cancer	0.000246	0.00164	CcSEcCtD
Rosiglitazone—Back pain—Doxorubicin—uterine cancer	0.000246	0.00164	CcSEcCtD
Rosiglitazone—Nausea—Etoposide—uterine cancer	0.000237	0.00159	CcSEcCtD
Rosiglitazone—Hypertension—Epirubicin—uterine cancer	0.000237	0.00159	CcSEcCtD
Rosiglitazone—Anaemia—Doxorubicin—uterine cancer	0.000235	0.00157	CcSEcCtD
Rosiglitazone—Arthralgia—Epirubicin—uterine cancer	0.000234	0.00156	CcSEcCtD
Rosiglitazone—Myalgia—Epirubicin—uterine cancer	0.000234	0.00156	CcSEcCtD
Rosiglitazone—Leukopenia—Doxorubicin—uterine cancer	0.000227	0.00152	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Epirubicin—uterine cancer	0.000224	0.0015	CcSEcCtD
Rosiglitazone—Oedema—Epirubicin—uterine cancer	0.000224	0.0015	CcSEcCtD
Rosiglitazone—Infection—Epirubicin—uterine cancer	0.000222	0.00149	CcSEcCtD
Rosiglitazone—Nervous system disorder—Epirubicin—uterine cancer	0.00022	0.00147	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Epirubicin—uterine cancer	0.000219	0.00147	CcSEcCtD
Rosiglitazone—Hypertension—Doxorubicin—uterine cancer	0.000219	0.00147	CcSEcCtD
Rosiglitazone—Arthralgia—Doxorubicin—uterine cancer	0.000216	0.00145	CcSEcCtD
Rosiglitazone—Myalgia—Doxorubicin—uterine cancer	0.000216	0.00145	CcSEcCtD
Rosiglitazone—Oedema—Doxorubicin—uterine cancer	0.000207	0.00139	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Doxorubicin—uterine cancer	0.000207	0.00139	CcSEcCtD
Rosiglitazone—Infection—Doxorubicin—uterine cancer	0.000206	0.00138	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000204	0.00137	CcSEcCtD
Rosiglitazone—Nervous system disorder—Doxorubicin—uterine cancer	0.000203	0.00136	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Doxorubicin—uterine cancer	0.000203	0.00136	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000193	0.00129	CcSEcCtD
Rosiglitazone—Fatigue—Epirubicin—uterine cancer	0.000193	0.00129	CcSEcCtD
Rosiglitazone—Constipation—Epirubicin—uterine cancer	0.000191	0.00128	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000189	0.00126	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000179	0.0012	CcSEcCtD
Rosiglitazone—Fatigue—Doxorubicin—uterine cancer	0.000179	0.0012	CcSEcCtD
Rosiglitazone—Urticaria—Epirubicin—uterine cancer	0.000178	0.00119	CcSEcCtD
Rosiglitazone—Constipation—Doxorubicin—uterine cancer	0.000177	0.00119	CcSEcCtD
Rosiglitazone—Urticaria—Doxorubicin—uterine cancer	0.000165	0.0011	CcSEcCtD
Rosiglitazone—Asthenia—Epirubicin—uterine cancer	0.000161	0.00108	CcSEcCtD
Rosiglitazone—Pruritus—Epirubicin—uterine cancer	0.000158	0.00106	CcSEcCtD
Rosiglitazone—Diarrhoea—Epirubicin—uterine cancer	0.000153	0.00103	CcSEcCtD
Rosiglitazone—Asthenia—Doxorubicin—uterine cancer	0.000149	0.000995	CcSEcCtD
Rosiglitazone—Dizziness—Epirubicin—uterine cancer	0.000148	0.000992	CcSEcCtD
Rosiglitazone—Pruritus—Doxorubicin—uterine cancer	0.000147	0.000982	CcSEcCtD
Rosiglitazone—Diarrhoea—Doxorubicin—uterine cancer	0.000142	0.000949	CcSEcCtD
Rosiglitazone—Rash—Epirubicin—uterine cancer	0.000141	0.000945	CcSEcCtD
Rosiglitazone—Dermatitis—Epirubicin—uterine cancer	0.000141	0.000945	CcSEcCtD
Rosiglitazone—Headache—Epirubicin—uterine cancer	0.00014	0.000939	CcSEcCtD
Rosiglitazone—Dizziness—Doxorubicin—uterine cancer	0.000137	0.000917	CcSEcCtD
Rosiglitazone—Nausea—Epirubicin—uterine cancer	0.000133	0.000891	CcSEcCtD
Rosiglitazone—Rash—Doxorubicin—uterine cancer	0.000131	0.000875	CcSEcCtD
Rosiglitazone—Dermatitis—Doxorubicin—uterine cancer	0.00013	0.000874	CcSEcCtD
Rosiglitazone—Headache—Doxorubicin—uterine cancer	0.00013	0.000869	CcSEcCtD
Rosiglitazone—Nausea—Doxorubicin—uterine cancer	0.000123	0.000824	CcSEcCtD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.54e-05	0.00115	CbGpPWpGaD
Rosiglitazone—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	5.43e-05	0.00113	CbGpPWpGaD
Rosiglitazone—ALB—Platelet degranulation—VEGFA—uterine cancer	5.41e-05	0.00113	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	5.36e-05	0.00112	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—STAR—uterine cancer	5.28e-05	0.0011	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—AKR1B1—uterine cancer	5.28e-05	0.0011	CbGpPWpGaD
Rosiglitazone—PPARG—Generic Transcription Pathway—ESR1—uterine cancer	5.26e-05	0.0011	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—POLD1—uterine cancer	5.26e-05	0.0011	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.22e-05	0.00109	CbGpPWpGaD
Rosiglitazone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	5.15e-05	0.00107	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	5.01e-05	0.00104	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5e-05	0.00104	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—MET—uterine cancer	4.98e-05	0.00104	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.97e-05	0.00104	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—AKR1C1—uterine cancer	4.92e-05	0.00102	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—TP53—uterine cancer	4.77e-05	0.000993	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—PGR—uterine cancer	4.75e-05	0.000989	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.74e-05	0.000987	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.74e-05	0.000987	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—STAR—uterine cancer	4.7e-05	0.000978	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—AKR1B1—uterine cancer	4.7e-05	0.000978	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.64e-05	0.000967	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—EZH2—uterine cancer	4.51e-05	0.000939	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.46e-05	0.000929	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—STAR—uterine cancer	4.44e-05	0.000925	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—AKR1B1—uterine cancer	4.44e-05	0.000925	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—RRM2—uterine cancer	4.39e-05	0.000913	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—TP53—uterine cancer	4.35e-05	0.000905	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—DCN—uterine cancer	4.26e-05	0.000887	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	4.26e-05	0.000886	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NDUFB11—uterine cancer	4.2e-05	0.000874	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—SRD5A2—uterine cancer	4.2e-05	0.000874	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—IRF1—uterine cancer	4.18e-05	0.000871	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—ESR2—uterine cancer	4.18e-05	0.00087	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—SRD5A2—uterine cancer	4.17e-05	0.000869	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NDUFB11—uterine cancer	4.17e-05	0.000869	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—POLD1—uterine cancer	4.14e-05	0.000863	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.08e-05	0.000849	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.07e-05	0.000847	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.05e-05	0.000844	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—PTEN—uterine cancer	4.02e-05	0.000837	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CYP11A1—uterine cancer	4.01e-05	0.000835	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—AKR1C1—uterine cancer	3.87e-05	0.000807	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.85e-05	0.000802	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—EP300—uterine cancer	3.83e-05	0.000798	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.83e-05	0.000797	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—AKR1C3—uterine cancer	3.79e-05	0.000789	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NDUFB11—uterine cancer	3.74e-05	0.00078	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—SRD5A2—uterine cancer	3.74e-05	0.00078	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—POLD1—uterine cancer	3.68e-05	0.000767	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.64e-05	0.000758	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—ERBB2—uterine cancer	3.64e-05	0.000758	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—POLD1—uterine cancer	3.48e-05	0.000726	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.48e-05	0.000724	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—RRM2—uterine cancer	3.45e-05	0.000719	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—AKR1C1—uterine cancer	3.45e-05	0.000718	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NDUFB11—uterine cancer	3.44e-05	0.000717	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—SRD5A2—uterine cancer	3.44e-05	0.000717	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.43e-05	0.000715	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—SRD5A2—uterine cancer	3.41e-05	0.000711	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NDUFB11—uterine cancer	3.41e-05	0.000711	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—CDKN2B—uterine cancer	3.4e-05	0.000709	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—DCN—uterine cancer	3.35e-05	0.000698	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.32e-05	0.000691	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—AKR1C1—uterine cancer	3.26e-05	0.000679	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—CTNNB1—uterine cancer	3.18e-05	0.000663	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CYP11A1—uterine cancer	3.16e-05	0.000658	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.13e-05	0.000652	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—SMAD3—uterine cancer	3.11e-05	0.000647	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—RRM2—uterine cancer	3.07e-05	0.00064	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—STAR—uterine cancer	3.03e-05	0.000632	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—AKR1B1—uterine cancer	3.03e-05	0.000632	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—AKR1B1—uterine cancer	3.02e-05	0.000628	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—STAR—uterine cancer	3.02e-05	0.000628	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3e-05	0.000624	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—AKR1C3—uterine cancer	2.98e-05	0.000621	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—DCN—uterine cancer	2.98e-05	0.000621	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.98e-05	0.000621	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—EP300—uterine cancer	2.96e-05	0.000616	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—STK11—uterine cancer	2.95e-05	0.000615	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CYP19A1—uterine cancer	2.95e-05	0.000615	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—SRD5A2—uterine cancer	2.92e-05	0.000608	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NDUFB11—uterine cancer	2.92e-05	0.000608	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—RRM2—uterine cancer	2.9e-05	0.000605	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—PIK3CA—uterine cancer	2.84e-05	0.000591	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.83e-05	0.00059	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—DCN—uterine cancer	2.82e-05	0.000587	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CYP11A1—uterine cancer	2.81e-05	0.000585	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—VEGFA—uterine cancer	2.8e-05	0.000583	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.77e-05	0.000577	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—NRAS—uterine cancer	2.77e-05	0.000576	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—AKR1B1—uterine cancer	2.71e-05	0.000564	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—STAR—uterine cancer	2.71e-05	0.000564	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.68e-05	0.000557	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.68e-05	0.000557	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CYP11A1—uterine cancer	2.66e-05	0.000553	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—AKR1C3—uterine cancer	2.65e-05	0.000553	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.64e-05	0.00055	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—ESR1—uterine cancer	2.53e-05	0.000528	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—AKR1C3—uterine cancer	2.51e-05	0.000523	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—AKR1B1—uterine cancer	2.49e-05	0.000519	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—STAR—uterine cancer	2.49e-05	0.000519	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—AKR1B1—uterine cancer	2.47e-05	0.000514	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—STAR—uterine cancer	2.47e-05	0.000514	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.44e-05	0.000508	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	2.4e-05	0.0005	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—KRAS—uterine cancer	2.38e-05	0.000496	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—POLD1—uterine cancer	2.38e-05	0.000496	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—POLD1—uterine cancer	2.37e-05	0.000493	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CYP19A1—uterine cancer	2.32e-05	0.000484	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—STK11—uterine cancer	2.32e-05	0.000484	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—AKT1—uterine cancer	2.32e-05	0.000482	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—AKR1C1—uterine cancer	2.23e-05	0.000464	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—MTHFR—uterine cancer	2.22e-05	0.000462	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—AKR1C1—uterine cancer	2.21e-05	0.000461	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.18e-05	0.000454	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—POLD1—uterine cancer	2.12e-05	0.000442	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—AKR1B1—uterine cancer	2.11e-05	0.000439	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—STAR—uterine cancer	2.11e-05	0.000439	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.09e-05	0.000434	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.08e-05	0.000433	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CYP19A1—uterine cancer	2.07e-05	0.000431	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—STK11—uterine cancer	2.07e-05	0.000431	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—HRAS—uterine cancer	2.02e-05	0.000422	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.99e-05	0.000414	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—RRM2—uterine cancer	1.98e-05	0.000413	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—RRM2—uterine cancer	1.97e-05	0.000411	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CYP19A1—uterine cancer	1.95e-05	0.000407	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—STK11—uterine cancer	1.95e-05	0.000407	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.95e-05	0.000407	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—POLD1—uterine cancer	1.95e-05	0.000407	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.94e-05	0.000404	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—POLD1—uterine cancer	1.94e-05	0.000403	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—DCN—uterine cancer	1.93e-05	0.000401	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—DCN—uterine cancer	1.92e-05	0.000399	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	1.87e-05	0.00039	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.85e-05	0.000385	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.83e-05	0.000381	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.81e-05	0.000378	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.81e-05	0.000377	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CYP11A1—uterine cancer	1.8e-05	0.000376	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—AKT1—uterine cancer	1.79e-05	0.000372	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—RRM2—uterine cancer	1.77e-05	0.000369	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—MTHFR—uterine cancer	1.75e-05	0.000364	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—DCN—uterine cancer	1.72e-05	0.000358	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.71e-05	0.000357	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—AKR1C3—uterine cancer	1.7e-05	0.000355	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—POLD1—uterine cancer	1.66e-05	0.000345	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—RRM2—uterine cancer	1.63e-05	0.000339	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.62e-05	0.000337	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—RRM2—uterine cancer	1.61e-05	0.000336	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—DCN—uterine cancer	1.58e-05	0.000329	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—DCN—uterine cancer	1.57e-05	0.000327	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—MTHFR—uterine cancer	1.55e-05	0.000324	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.55e-05	0.000322	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.54e-05	0.00032	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.53e-05	0.000319	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.53e-05	0.000319	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.49e-05	0.00031	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.48e-05	0.000308	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—MTHFR—uterine cancer	1.47e-05	0.000306	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.41e-05	0.000293	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.39e-05	0.000291	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—RRM2—uterine cancer	1.38e-05	0.000287	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.37e-05	0.000285	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—DCN—uterine cancer	1.34e-05	0.000279	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.34e-05	0.000278	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—STK11—uterine cancer	1.34e-05	0.000278	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—STK11—uterine cancer	1.33e-05	0.000277	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CYP19A1—uterine cancer	1.33e-05	0.000277	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—EP300—uterine cancer	1.31e-05	0.000272	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.26e-05	0.000263	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.25e-05	0.000261	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.25e-05	0.00026	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—VEGFA—uterine cancer	1.24e-05	0.000258	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PTEN—uterine cancer	1.23e-05	0.000257	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—NRAS—uterine cancer	1.22e-05	0.000254	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.2e-05	0.000249	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.19e-05	0.000248	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—STK11—uterine cancer	1.19e-05	0.000248	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP19A1—uterine cancer	1.19e-05	0.000248	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.19e-05	0.000248	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—EP300—uterine cancer	1.18e-05	0.000245	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.12e-05	0.000233	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—STK11—uterine cancer	1.1e-05	0.000228	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.1e-05	0.000228	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—STK11—uterine cancer	1.09e-05	0.000226	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.09e-05	0.000226	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.07e-05	0.000222	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—KRAS—uterine cancer	1.05e-05	0.000219	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.02e-05	0.000212	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—MTHFR—uterine cancer	1e-05	0.000209	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—MTHFR—uterine cancer	9.98e-06	0.000208	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.73e-06	0.000203	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PTEN—uterine cancer	9.71e-06	0.000202	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PIK3CA—uterine cancer	9.66e-06	0.000201	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TP53—uterine cancer	9.34e-06	0.000195	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—STK11—uterine cancer	9.29e-06	0.000193	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP19A1—uterine cancer	9.29e-06	0.000193	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—EP300—uterine cancer	9.26e-06	0.000193	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—AKT1—uterine cancer	9.14e-06	0.00019	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—MTHFR—uterine cancer	8.96e-06	0.000187	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—HRAS—uterine cancer	8.93e-06	0.000186	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.84e-06	0.000184	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.79e-06	0.000183	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.72e-06	0.000182	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PIK3CA—uterine cancer	8.7e-06	0.000181	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PTEN—uterine cancer	8.64e-06	0.00018	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.31e-06	0.000173	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—EP300—uterine cancer	8.24e-06	0.000172	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—MTHFR—uterine cancer	8.24e-06	0.000172	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PTEN—uterine cancer	8.17e-06	0.00017	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—MTHFR—uterine cancer	8.17e-06	0.00017	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.89e-06	0.000164	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—AKT1—uterine cancer	7.89e-06	0.000164	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—EP300—uterine cancer	7.79e-06	0.000162	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.2e-06	0.00015	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—AKT1—uterine cancer	7.11e-06	0.000148	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—MTHFR—uterine cancer	6.98e-06	0.000145	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CA—uterine cancer	6.85e-06	0.000143	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.15e-06	0.000128	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CA—uterine cancer	6.1e-06	0.000127	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CA—uterine cancer	5.76e-06	0.00012	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—AKT1—uterine cancer	5.6e-06	0.000117	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PTEN—uterine cancer	5.58e-06	0.000116	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PTEN—uterine cancer	5.55e-06	0.000116	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—EP300—uterine cancer	5.32e-06	0.000111	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—EP300—uterine cancer	5.29e-06	0.00011	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PTEN—uterine cancer	4.98e-06	0.000104	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—AKT1—uterine cancer	4.98e-06	0.000104	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—EP300—uterine cancer	4.75e-06	9.9e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—AKT1—uterine cancer	4.71e-06	9.81e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PTEN—uterine cancer	4.58e-06	9.54e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PTEN—uterine cancer	4.54e-06	9.46e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—EP300—uterine cancer	4.37e-06	9.1e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—EP300—uterine cancer	4.33e-06	9.02e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CA—uterine cancer	3.94e-06	8.2e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CA—uterine cancer	3.92e-06	8.15e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PTEN—uterine cancer	3.88e-06	8.09e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—EP300—uterine cancer	3.7e-06	7.71e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CA—uterine cancer	3.51e-06	7.32e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CA—uterine cancer	3.23e-06	6.73e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—AKT1—uterine cancer	3.22e-06	6.7e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.2e-06	6.67e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—AKT1—uterine cancer	3.2e-06	6.66e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—AKT1—uterine cancer	2.87e-06	5.98e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.74e-06	5.7e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—AKT1—uterine cancer	2.64e-06	5.5e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—AKT1—uterine cancer	2.62e-06	5.45e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—AKT1—uterine cancer	2.24e-06	4.66e-05	CbGpPWpGaD
